A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of 68Ga-DOTATATE in patients without neuroendocrine tumors
Open Access
- 16 August 2021
- journal article
- research article
- Published by Springer Nature in EJNMMI Research
- Vol. 11 (1) , 1-12
Abstract
Background: Physiologically based pharmacokinetic (PBPK) models combine drug-specific information with prior knowledge on the physiology and biology at the organism level. Whole-body PBPK models contain an explicit representation of the organs and tissue and are a tool to predict pharmacokinetic behavior of drugs. The aim of this study was to develop a PBPK model to describe organ distribution of 68Ga-DOTATATE in a population of patients without detectable neuroendocrine tumors (NETs). Methods: Clinical 68Ga-DOTATATE PET/CT data from 41 patients without any detectable somatostatin receptor (SSTR) overexpressing tumors were included. Scans were performed at 45 min (range 30–60 min) after intravenous bolus injection of 68Ga-DOTATATE. Organ (spleen, liver, thyroid) and blood activity levels were derived from PET scans, and corresponding DOTATATE concentrations were calculated. A whole-body PBPK model was developed, including an internalization reaction, receptor recycling, enzymatic reaction for intracellular degradation and renal clearance. SSTR2 expression was added for several organs. Input parameters were fixed or estimated using a built-in Monte Carlo algorithm for parameter identification. Results: 68Ga-DOTATATE was administered with a median peptide amount of 12.3 µg (range 8.05–16.9 µg) labeled with 92.7 MBq (range 43.4–129.9 MBq). SSTR2 amounts for spleen, liver and thyroid were estimated at 4.40, 7.80 and 0.0108 nmol, respectively. Variability in observed organ concentrations was best described by variability in SSTR2 expression and differences in administered peptide amounts. Conclusions: To conclude, biodistribution of 68Ga-DOTATATE was described with a whole-body PBPK model, where tissue distribution was mainly determined by variability in SSTR2 organ expression and differences in administered peptide amounts.Keywords
This publication has 49 references indexed in Scilit:
- Measured Human Dosimetry of68Ga-DOTATATEJournal of Nuclear Medicine, 2013
- Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapyMedical Physics, 2012
- Ligand-Dependent Mechanisms of sst2A Receptor Trafficking: Role of Site-Specific Phosphorylation and Receptor Activation in the Actions of Biased Somatostatin AgonistsMolecular Endocrinology, 2011
- Molecular imaging with 68Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2011
- Distribution pattern of 68Ga-DOTATATE in disease-free patientsNuclear Medicine Communications, 2010
- In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours — impact of peptide massNuclear Medicine and Biology, 2010
- Highly Efficient In Vivo Agonist-Induced Internalization of sst2 Receptors in Somatostatin Target TissuesJournal of Nuclear Medicine, 2009
- Derivation of a Compartmental Model for Quantifying 64Cu-DOTA-RGD Kinetics in Tumor-Bearing MiceJournal of Nuclear Medicine, 2009
- A methodology for performing global uncertainty and sensitivity analysis in systems biologyJournal of Theoretical Biology, 2008
- Somatostatin and Somatostatin Receptor PhysiologyEndocrine, 2003